ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2024 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) updated its FY 2024 earnings guidance on Friday. The company provided EPS guidance of 4.900-5.050 for the period, compared to the consensus EPS estimate of 4.720. The company issued revenue guidance of $594.0 million-$602.0 million, compared to the consensus revenue estimate of $590.3 million. ANI Pharmaceuticals also updated its FY24 guidance to $4.90-5.05 EPS.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Piper Sandler started coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an "overweight" rating and a $68.00 target price for the company. HC Wainwright restated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. StockNews.com cut ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Raymond James upped their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 18th. Finally, Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a report on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $77.33.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded up $3.06 on Friday, hitting $61.44. The company's stock had a trading volume of 348,398 shares, compared to its average volume of 215,677. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of 52.51 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81. The stock's 50-day moving average is $58.66 and its two-hundred day moving average is $61.55.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm had revenue of $138.00 million during the quarter, compared to analyst estimates of $129.09 million. During the same quarter in the prior year, the firm posted $1.06 EPS. ANI Pharmaceuticals's revenue was up 18.5% compared to the same quarter last year. On average, equities research analysts forecast that ANI Pharmaceuticals will post 3.5 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.